{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:10:34Z","timestamp":1790356234513,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.canlet.2011.08.026","type":"journal-article","created":{"date-parts":[[2011,9,7]],"date-time":"2011-09-07T07:34:46Z","timestamp":1315380886000},"page":"84-90","source":"Crossref","is-referenced-by-count":42,"title":["The cdk1-cyclin B complex is involved in everolimus triggered resistance in the PC3 prostate cancer cell line"],"prefix":"10.1016","volume":"313","author":[{"given":"Igor","family":"Tsaur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmina","family":"Makarevi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukasz","family":"Hudak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Juengel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kurosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wiesner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Bartsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Harder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Haferkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman A.","family":"Blaheta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2011.08.026_b0005","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"TAX 327 investigators, docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.canlet.2011.08.026_b0010","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2007.12.4008","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study","volume":"26","author":"Berthold","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2011.08.026_b0015","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2174\/157488711793980147","article-title":"Recent clinical trials of mTOR-targeted cancer therapies","volume":"6","author":"Don","year":"2011","journal-title":"Rev. Recent Clin. Trials"},{"key":"10.1016\/j.canlet.2011.08.026_b0020","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11523-011-0172-y","article-title":"Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma","volume":"6","author":"Pal","year":"2011","journal-title":"Target Oncol."},{"key":"10.1016\/j.canlet.2011.08.026_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2009.08.012","article-title":"Novel targeted therapeutics for metastatic castration-resistant prostate cancer","volume":"291","author":"Antonarakis","year":"2010","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2011.08.026_b0030","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11523-010-0149-2","article-title":"Perspectives in drug development for metastatic renal cell cancer","volume":"5","author":"Basu","year":"2010","journal-title":"Target Oncol."},{"key":"10.1016\/j.canlet.2011.08.026_b0035","doi-asserted-by":"crossref","first-page":"764s","DOI":"10.1158\/1078-0432.CCR-06-1975","article-title":"Opportunities and obstacles to combination targeted therapy in renal cell cancer","volume":"13","author":"Sosman","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2011.08.026_b0040","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/S1470-2045(09)70240-2","article-title":"Resistance to targeted therapy in renal-cell carcinoma","volume":"10","author":"Rini","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2011.08.026_b0045","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1158\/1078-0432.CCR-08-1893","article-title":"A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients","volume":"15","author":"Houk","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2011.08.026_b0050","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1200\/JCO.2008.19.3342","article-title":"Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma","volume":"27","author":"Escudier","year":"2009","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.canlet.2011.08.026_b0055","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1007\/s00018-002-8498-3","article-title":"Survival of docetaxel-resistant prostate cancer cells in vitro depends on phenotype alterations and continuity of drug exposure","volume":"59","author":"Makarovskiy","year":"2002","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.canlet.2011.08.026_b0060","first-page":"4667","article-title":"Paclitaxel-associated multimininucleation is permitted by the inhibition of caspase activation: a potential early step in drug resistance","volume":"58","author":"Panvichian","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2011.08.026_b0065","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00001813-200004000-00011","article-title":"Resistance to paclitaxel induces time-delayed multinucleation and DNA fragmentation into large fragments in MCF-7 human breast adenocarcinoma cells","volume":"11","author":"Merlin","year":"2000","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.canlet.2011.08.026_b0070","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1158\/1078-0432.CCR-10-1178","article-title":"Anaphase catastrophe is a target for cancer therapy","volume":"17","author":"Galimberti","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2011.08.026_b0075","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1158\/0008-5472.CAN-09-4094","article-title":"Low molecular weight cyclin E overexpression shortens mitosis leading to chromosome missegregation and centrosome amplification","volume":"70","author":"Bagheri-Yarmand","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2011.08.026_b0080","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1038\/onc.2010.165","article-title":"Deficiency in myosin light-chain phosphorylation causes cytokinesis failure and multipolarity in cancer cells","volume":"29","author":"Wu","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2011.08.026_b0085","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3109\/01913123.2010.543753","article-title":"Mitotic catastrophe in malignant epithelial tumors: the pathologist\u2019s viewpoint","volume":"35","author":"Caruso","year":"2011","journal-title":"Ultrastruct. Pathol."},{"key":"10.1016\/j.canlet.2011.08.026_b0090","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1038\/sj.bjc.6600862","article-title":"Antitumour effect of cyclin-dependent kinase inhibitors (p16(INK4A), p18(INK4C), p19(INK4D), p21(WAF1\/CIP1) and p27(KIP1)) on malignant glioma cells","volume":"88","author":"Komata","year":"2003","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2011.08.026_b0095","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/cncr.11079","article-title":"Low expression of p27 indicates a poor prognosis in patients with high-grade astrocytomas","volume":"97","author":"Kirla","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2011.08.026_b0100","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/hupa.2000.8227","article-title":"Cell cycle regulators in bladder cancer: a multivariate survival study with emphasis on p27Kip1","volume":"31","author":"Korkolopoulou","year":"2000","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.canlet.2011.08.026_b0105","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1158\/0008-5472.CAN-06-3066","article-title":"Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K\/mTOR\/ETS2 pathway","volume":"67","author":"Li","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2011.08.026_b0110","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.bbrc.2003.09.132","article-title":"Role of PI3K\/AKT\/mTOR signaling in the cell cycle progression of human prostate cancer","volume":"310","author":"Gao","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.canlet.2011.08.026_b0115","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.humpath.2010.10.006","article-title":"Subcellular localization of p27 and prostate cancer recurrence: automated digital microscopy analysis of tissue microarrays","volume":"42","author":"Ananthanarayanan","year":"2011","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.canlet.2011.08.026_b0120","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1464-410X.2009.08998.x","article-title":"The value of EZH2, p27(kip1), BMI-1 and MIB-1 on biopsy specimens with low-risk prostate cancer in selecting men with significant prostate cancer at prostatectomy","volume":"106","author":"Wolters","year":"2010","journal-title":"BJU Int."},{"key":"10.1016\/j.canlet.2011.08.026_b0125","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nature04809","article-title":"Identification of a tumour suppressor network opposing nuclear Akt function","volume":"441","author":"Trotman","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2011.08.026_b0130","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/pros.20398","article-title":"PI3K\/Akt signaling regulates p27(kip1) expression via Skp2 in PC3 and DU145 prostate cancer cells but is not a major factor in p27(kip1) regulation in LNCaP and PC346 cells","volume":"66","author":"van Duijn","year":"2006","journal-title":"Prostate"},{"key":"10.1016\/j.canlet.2011.08.026_b0135","doi-asserted-by":"crossref","first-page":"e18424","DOI":"10.1371\/journal.pone.0018424","article-title":"Targeted morphoproteomic profiling of Ewing\u2019s sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response\/resistance signatures","volume":"6","author":"Subbiah","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2011.08.026_b0140","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/ncb0805-779","article-title":"Cdk1: the dominant sibling of Cdk2","volume":"7","author":"Bashir","year":"2005","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.canlet.2011.08.026_b0145","doi-asserted-by":"crossref","first-page":"21643","DOI":"10.1073\/pnas.0903827106","article-title":"Temporal self-organization of the cyclin\/Cdk network driving the mammalian cell cycle","volume":"106","author":"G\u00e9rard","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.canlet.2011.08.026_b0150","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1158\/0008-5472.CAN-07-6656","article-title":"Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance","volume":"69","author":"Ihle","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2011.08.026_b0155","doi-asserted-by":"crossref","first-page":"6877","DOI":"10.1038\/sj.onc.1208851","article-title":"Sodium butyrate sensitizes human glioma cells to TRAIL-mediated apoptosis through inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP","volume":"24","author":"Kim","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2011.08.026_b0160","first-page":"6414","article-title":"Cyclin B1 overexpression and resistance to radiotherapy in head and neck squamous cell carcinoma","volume":"62","author":"Hassan","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2011.08.026_b0165","doi-asserted-by":"crossref","first-page":"e9197","DOI":"10.1371\/journal.pone.0009197","article-title":"Raptor is phosphorylated by cdc2 during mitosis","volume":"5","author":"Gwinn","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2011.08.026_b0170","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/jcp.20395","article-title":"Akt-induced promotion of cell-cycle progression at G2\/M phase involves upregulation of NF-Y binding activity in PC12 cells","volume":"205","author":"Lee","year":"2005","journal-title":"J. Cell Physiol."},{"key":"10.1016\/j.canlet.2011.08.026_b0175","doi-asserted-by":"crossref","unstructured":"D. Hiraoka, E. Okumura, T. Kishimoto, Turn motif phosphorylation negatively regulates activation loop phosphorylation in Akt, Oncogene, 2011. [Epub ahead of print].","DOI":"10.1038\/onc.2011.155"},{"key":"10.1016\/j.canlet.2011.08.026_b0180","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1007\/s00018-005-5027-1","article-title":"Antiproliferative effect of beta-elemene in chemoresistant ovarian carcinoma cells is mediated through arrest of the cell cycle at the G2-M phase","volume":"62","author":"Li","year":"2005","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.canlet.2011.08.026_b0185","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/sj.onc.1208241","article-title":"Rottlerin sensitizes glioma cells to TRAIL-induced apoptosis by inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP","volume":"24","author":"Kim","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2011.08.026_b0190","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1158\/1535-7163.MCT-10-0562","article-title":"Combination of vorinostat and flavopiridol is selectively cytotoxic to multidrug-resistant neuroblastoma cell lines with mutant TP53","volume":"9","author":"Huang","year":"2010","journal-title":"Mol. Cancer Ther."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383511005143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383511005143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,15]],"date-time":"2019-06-15T01:57:14Z","timestamp":1560563834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383511005143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0304383511005143"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2011.08.026","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}